{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.575","value":"89.1390"},{"groupId":"OG001","spread":"27.249","value":"98.3568"},{"groupId":"OG002","spread":"22.221","value":"109.5502"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.860","value":"87.5544"},{"groupId":"OG001","spread":"14.411","value":"90.7844"},{"groupId":"OG002","spread":"13.679","value":"136.2193"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Elimination half-life of melphalan","dispersionType":"Standard Deviation","groups":[{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg.","id":"OG000","title":"Cohort 1a, Melflufen 40 mg"},{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg.","id":"OG001","title":"Cohort 1b, Melflufen 30 mg"},{"description":"Patients with severe renal impairment (eGFR ≥15 to \\<30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg.","id":"OG002","title":"Cohort 2a, Melflufen 20 mg"}],"paramType":"MEAN","populationDescription":"Some patients were not evaluable for PK and were excluded from Cycle 1 and/or Cycle 2.","reportingStatus":"POSTED","timeFrame":"Samples were drawn 5-10 minutes after the end of infusion, 2-3 hours after the end of infusion, and 5-7 hours after the end of infusion.","title":"T1/2 of Melphalan","type":"PRIMARY","unitOfMeasure":"minutes"}